S. Akkoç and Y. Gök
suppliers (Merck, Aldrich, Alfa-Aesar and Fluka). CDCl3 and DMSO-d6
were used as solvents in all 1H NMR and 13C NMR analyses.
(CH3)4-3,5); 50.8 (NCH2C6H(CH3)4-2,3,5,6); 110.7, 128.6, 130.7, 132.3,
134.3, 135.0 (C6H4); 123.1, 128.3, 134.0, 135.6 (NCH2C6H(CH3)4);
111.9, 122.7, 128.9, 137.9 (NC6H5); 182.8 (C–Pd). Elemental analysis.
Calcd for C48H48N4PdCl2 (858.25 g/mol) (%): C, 67.17; H, 5.64; N, 6.53.
Found (%): C, 67.24; H, 5.54; N, 6.54.
The 1H NMR and 13C NMR spectra were obtained using a Bruker
AC300P FT spectrometer operating at 300.13 MHz (1H) and 75.47
MHz (13C). Chemical shifts were measured relative to tetra-
methylsilane. Coupling constants (J) were measured in Hz. The FT-
IR spectra were recorded with a Mattson 1000 spectrophotometer
and wavenumbers were recorded in cmꢀ1. Melting points were
determined in open capillary tubes with an Electrothermal-9200
melting point device. GC analysis was conducted with an Agilent
6890N Network GC system using an HP-5 column (column length
30 m, column diameter 0.32 mm, column filler size 0.25 μm) and
a temperature range from ꢀ60 to 325°C. Elemental analyses were
performed using CHNS-932 LECO apparatus.
Bis[1-phenyl-3-(2,3,4,5,6-pentamethylbenzyl)benzimidazol-2-ylidene]dichloro-
palladium(II) complex (2c)
Complex 2c, using the same conditions and procedure as for 2a, was
prepared from chloro [1-phenyl-3-(2,3,4,5,6-pentamethylbenzyl)
benzimidazol-2-ylidene]silver(I) complex (1c) (0.21 g, 0.42 mmol)
and PdCl2(PhCN)2 (0.08 g, 0.21 mmol) in dichloromethane (4 ml).
Cream-coloured powder; yield 87%; m.p. 294–295°C; ν(CN)
=
1473.48 cmꢀ1. 1H NMR (300.13 MHz, CDCl3, δ, ppm): 2.29 (s, 12 H,
NCH2C6(CH3)5-2,6); 2.36 (s, 6 H, NCH2C6(CH3)5-4); 2.45 (s, 12 H,
NCH2C6(CH3)5-3,5); 6.27 (s, 4 H, NCH2C6(CH3)5-2,3,4,5,6); 6.79–7.62
(m, 18 H, NC6H5 and C6H4). 13C NMR (75.47 MHz, CDCl3, δ, ppm):
16.9 (NCH2C6(CH3)5-2,6); 17.3 (NCH2C6(CH3)5-4); 17.5 (NCH2C6(CH3)
5-3,5); 53.3 (NCH2C6(CH3)5-2,3,4,5,6); 125.3, 126.1, 128.3, 137.3
(NC6H5); 122.4, 130.6, 131.8, 132.8, 134.8, 135.9 (C6H4); 127.7,
129.1, 133.9, 136.7 (NCH2C6(CH3)5); 166.2 (C–Pd). Elemental analysis.
Calcd for C50H52N4PdCl2 (886.3 g/mol) (%): C, 67.76; H, 5.91; N, 6.32.
Found (%): C, 67.70; H, 5.91; N, 6.32.
Syntheses
Complexes 1a–1h
1,3-Dialkyl-substituted silver NHC complexes 1a–1h containing
both electron-donating and electron-withdrawing moieties were
synthesized from the deprotonation of benzimidazolium salts, as
in our previous study.[28–30]
Bis[1-phenyl-3-(2,4,6-trimethylbenzyl)benzimidazol-2-ylidene]dichloropalladium
(II) complex (2a)
Bis[1-phenyl-3-(3,4,5-trimethoxybenzyl)benzimidazol-2-ylidene]dichloropal-
Chloro [1-phenyl-3-(2,4,6-trimethylbenzyl)benzimidazol-2-ylidene]
silver(I) complex (1a) (0.195 g, 0.42 mmol) and PdCl2(PhCN)2
(0.08g, 0.21 mmol) were dissolved in dried dichloromethane (4 ml)
and then were stirred at room temperature for 18 h in a Schlenk-
type flask. The flask was covered with aluminium foil to avoid light
exposure. The resulting cream-brown solution was filtered over
celite, silica gel and cotton. Then, the solvent was removed under
reduced pressure. The resulting product was crystallized from
dichloromethane–hexane mixture (2:1) at 25°C. Finally, the obtained
crystals were washed twice with 10 ml of diethyl ether and dried
under vacuum.
ladium(II) complex (2d)
Complex 2d, using the same conditions and procedure as for 2a,
was prepared from chloro [1-phenyl-3-(3,4,5-trimethoxybenzyl)
benzimidazol-2-ylidene]silver(I) complex (1d) (0.22 g, 0.42 mmol)
and PdCl2(PhCN)2 (0.08 g, 0.21 mmol) in dichloromethane (4 ml).
Cream-coloured powder; yield 83%; m.p. 305–306°C; ν(CN)
=
1
1590.51 cmꢀ1. H NMR (300.13 MHz, CDCl3, δ, ppm): 3.81, 3.91
(m, 18 H, NCH2C6H2(OCH3)3-3,4,5); 5.86 (s, 4 H, NCH2C6H2(OCH3)
3-3,4,5); 6.65 (s, 4 H, NCH2C6H2(OCH3)3-3,4,5); 7.06–8.04 (m, 18 H,
NC6H5 and C6H4). 13C NMR (75.47 MHz, CDCl3, δ, ppm): 52.9
(NCH2C6H2(OCH3)3-4);
56.8
(NCH2C6H2(OCH3)3-3,5);
60.8
Light cream-coloured powder; yield 85%; m.p. 312–313°C; ν(CN)
=
(NCH2C6H2(OCH3)3-3,4,5); 105.3, 131.2, 134.0, 153.6 (NCH2C6H2
(OCH3)3-3,4,5); 111.4, 123.6, 127.2, 128.4, 129.1, 135.3, 137.7
(NC6H5 and C6H4); 182.1 (C–Pd). Elemental analysis. Calcd for
C46H44N4O6PdCl2 (926.19 g/mol) (%): C, 59.65; H, 4.79; N, 6.05.
Found: C, 59.71; H, 4.78; N, 6.02.
1596.47 cmꢀ1. 1H NMR (300.13 MHz, CDCl3, δ, ppm): 2.31 (s, 12 H,
NCH2C6H2(CH3)3-2,6); 2.40 (s, 6 H, NCH2C6H2(CH3)3-4); 5.89 (s, 4 H,
NCH2C6H2(CH3)3-2,4,6); 6.42 (s, 4 H, NCH2C6H2(CH3)3-2,4,6); 6.95–
7.28 (m, 8 H, C6H4); 7.32–8.09 (m, 10 H, NC6H5). 13C NMR (75.47
MHz, CDCl3, δ, ppm): 20.9 (NCH2C6H2(CH3)3-2,6); 21.2 (NCH2C6H2
(CH3)3-4); 49.9 (NCH2C6H2(CH3)3-2,4,6); 111.8 (NCCHCHCHCHCH-
4); 122.8 (NCCHCHCHCHCH-2,6); 128.3 (NCCHCHCHCHCH-3,5);
138.7 (NCCHCHCHCHCH-1); 110.8, 123.2, 127.8, 128.9 (NCCH-
CHCHCHCN); 134.2, 138.2 (NCCHCHCHCHCN); 128.7, 129.5, 135.6,
137.9 (NCH2C6H2(CH3)3); 182.8 (C–Pd). Elemental analysis. Calcd for
C46H44N4PdCl2 (830.19 g/mol) (%): C, 66.55; H, 5.34; N, 6.75. Found
(%): C, 66.59; H, 5.27; N, 6.74.
Bis[1-(2-diethylaminoethyl)-3-(3-methylbenzyl)benzimidazol-2-ylidene]dichloro-
palladium(II) complex (2e)
Complex 2e, using the same conditions and procedure as for 2a,
was prepared from chloro [1-(2-diethylaminoethyl)-3-(3-methyl-
benzyl)benzimidazol-2-ylidene]silver(I) complex (1e) (0.19 g, 0.41
mmol) and PdCl2(PhCN)2 (0.08 g, 0.21 mmol) in dichloromethane (4
ml).
Bis[1-phenyl-3-(2,3,5,6-tetramethylbenzyl)benzimidazol-2-ylidene]dichloropalla-
dium(II) complex (2b)
Cream-coloured powder; yield 79%; ν(CN) = 1523.17 cmꢀ1 1H
.
NMR (300.13 MHz, DMSO, δ, ppm): 1.06 (t, 12 H, J= 7.6 Hz,
NCH2CH2N(CH2CH3)2); 2.28 (s, 6 H, NCH2C6H4CH3-3); 3.66 (m, 8 H,
NCH2CH2N(CH2CH3)2); 3.85 (m, 4 H, NCH2CH2N(CH2CH3)2); 5.37 v
(m, 4 H, NCH2CH2N(CH2CH3)2); 6.22 (s, 4 H, NCH2C6H4CH3-3); 7.01–
8.02 (m, 16 H, NCH2C6H4CH3-3 and C6H4). 13C NMR (75.47 MHz,
DMSO, δ, ppm): 12.9 (NCH2CH2N(CH2CH3)2); 19.9 (NCH2C6H4CH3-
3); 21.3 (NCH2CH2N(CH2CH3)2); 46.5 (NCH2CH2N(CH2CH3)2);
47.6 (NCH2CH2N(CH2CH3)2); 50.6 (NCH2C6H4CH3-3); 124.2, 125.3,
128.0, 128.9, 133.9, 138.0, 138.4 (NCH2C6H4CH3-3 and C6H4); 183.2
(C–Pd). Elemental analysis. Calcd for C42H54N6PdCl2 (820.24 g/mol) (%):
C, 61.50; H, 6.64; N, 10.25. Found (%): C, 61.59; H, 6.54; N, 10.25.
Complex 2b, using the same conditions and procedure as for 2a,
was prepared from chloro [1-phenyl-3-(2,3,5,6-tetramethylbenzyl)
benzimidazol-2-ylidene]silver(I) complex (1b) (0.201 g, 0.42 mmol)
and PdCl2(PhCN)2 (0.08 g, 0.21 mmol) in dichloromethane (4 ml).
Light yellow-coloured powder; yield 89%; m.p. 317–318°C; ν(CN)
=
1596.68 cmꢀ1. 1H NMR (300.13 MHz, CDCl3, δ, ppm): 2.39 (s, 12 H,
NCH2C6H(CH3)4-2,6); 2.56 (s, 12 H, NCH2C6H(CH3)4-3,5); 5.99 (s, 4 H,
NCH2C6H(CH3)4-2,3,5,6); 6.26 (s, 2 H, NCH2C6H(CH3)4-2,3,5,6); 6.98–
7.40 (m, 8 H, C6H4); 7.50–8.09 (m, 10 H, NC6H5). 13C NMR (75.47
MHz, CDCl3, δ, ppm): 16.5 (NCH2C6H(CH3)4-2,6); 20.6 (NCH2C6H
wileyonlinelibrary.com/journal/aoc
Copyright © 2014 John Wiley & Sons, Ltd.
Appl. Organometal. Chem. (2014)